bay2328065
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 21, 2018 (NCT03427788)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- P2X purinoceptor 3ANTAGONIST
P2RX3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04851483 | Phase 1 | Apr 28, 2021 | Bayer |
| NCT04027192 | Phase 1 | Jul 28, 2019 | Bayer |
| NCT03427788 | Phase 1 | Mar 21, 2018 | Bayer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 3 | 3 | 1 | 2018 |
1 organizations
Page 1 / 1